Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

BACKGROUND: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. METHODS: An...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Sweiss, Nadera J., Noth, Imre, Mirsaeidi, Mehdi, Zhang, Wei, Naureckas, Edward T., Hogarth, D. Kyle, Strek, Mary, Caligiuri, Philip, Machado, Roberto F, Niewold, Timothy B, Garcia, Joe G.N., Pangan, Aileen L., Baughman, Robert P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134103/
https://ncbi.nlm.nih.gov/pubmed/24751453
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller